News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Oxygen Biotherapeutics, Inc. (OXBT) Late-Stage Clinical Trials Could Bode Well For Shareholders Analyst Reports

5/12/2014 8:26:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

, May 12, 2014 /PRNewswire/ -- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) Today, approximately 8% of the world's population is over the age of 65; and that number is expected to double in less than 40 years. As the world's population ages in the coming years, the demand for critical care services will undoubtedly increase in both developed and underdeveloped countries across the world. In fact, GBI Research estimates that the size of this market will grow from $2.3 billion in 2012 to $3.2 billion in 2019.

Just one example within this critical care market can be seen in the case of heart failure, which affects more than 20 million people around the world with nearly a quarter of occurrences here in the US. Considering most people suffering from chronic heart failure, or more specifically Acute Decompensated Heart Failure (ADHF), are over the age of 65, the likelihood of incidences increasing in the future is high. One such company that should benefit from the growth in this market, and the critical care market in general, is Oxygen Biotherapeutics.

Oxygen Biotherapeutics is a specialty pharmaceutical company focused on developing and commercializing drugs for critical care patients. The company's efforts are centered on two of their lead products Levosimendan and Oxycyte. Levosimendan is primarily for use in patients with ADHF and Low Cardiac Output Syndrome (LCOS), while Oxycyte is currently being evaluated for the treatment of traumatic brain injury (TBI), decompression illness (DCI) aka "the bends" and stroke.

A full in-depth analyst report on OXBT that includes risk factors, industry review, financial position, potential revenues, review of current business model, competition breakdown, analyst summary, and recommendation can be viewed by using the following link at no cost:

Copy and paste to browser may be required.


This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.


Content is researched, written and reviewed on a best-effort basis. The research report is written and authored by Michael Maggi, CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

A full disclaimer can be found by viewing the full analyst report.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Small Cap Specialists, LLC

Help employers find you! Check out all the jobs and post your resume.
Read at

comments powered by Disqus